Plasmid DNA and Advanced Therapies: Accelerating Path to Clinic
Webinar in collaboration with BioWin
Date: December 8, 2022
Time: 14:00 CET/ 13:00 GMT/ 08:00 EST
Webinar in collaboration with BioWin
Abstract
Gene therapies and emerging biomodalities are developing at an unprecedent pace, improving the lives of patients around the world. The high demand for those treatments opens a competitive market in which faster and high-quality cost-effective solutions are a clear advantage. The starting point for advanced therapies is generally DNA in the shape of plasmid DNA (pDNA). GMP requirements from early stage, together with the right tools and analytics providing the highest quality standards for pDNA, will ensure successful downstream applications as AAV, from early clinical development to commercial phase.
Join this webinar for an in-depth discussion of the challenges CGT innovators face and how experts resolve these barriers through adopting technology and strategy that drive an optimized plasmid production process and supply.
Key learning objectives
1. Learn the current plasmid DNA manufacturing landscape.
2. Discuss key considerations during plasmid production, including design and screening system and processing.
3. Discuss main challenges linked to GMP pDNA production and the impact on different advanced therapy programs.
Speakers:
· Nuria Gomez Santos, Ph.D,
Head of Process & Analytical Development, pDNA
· Prof Eli Keshavarz-Moore, Professor of Bioprocess Science & Enterprise, Dept of Biochemical Engineering, Faculty of Engineering Science, UCL
Moderator:
Thierry Ferain, Director Innovation & Growth, BioWin